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Esophageal cancer is the third most diagnosed cancer and the fourth leading cause of cancer death in China.[1](#cas13130-bib-0001){ref-type="ref"} Esophageal squamous cell carcinoma is the predominant histologic type (90--95%); the incidence of esophageal adenocarcinoma remains extremely low in China.[2](#cas13130-bib-0002){ref-type="ref"} Epidemiological and etiological studies have shown that environmental and genetic factors have important roles in esophageal carcinogenesis.[3](#cas13130-bib-0003){ref-type="ref"}, [4](#cas13130-bib-0004){ref-type="ref"} A series of studies have shown that tobacco smoking, heavy alcohol drinking, nutritional deficiencies, and dietary carcinogen exposure may cause this malignancy.[5](#cas13130-bib-0005){ref-type="ref"} There is a strong tendency toward familial aggregation of ESCC in the high incident rates of ESCC, suggesting that genetic susceptibility, in combination with exposure to environmental risk factors, contributes to ESCC.[6](#cas13130-bib-0006){ref-type="ref"} However, the exact mechanism for the carcinogenesis of ESCC is still unclear.

Up to now, three ESCC GWAS[6](#cas13130-bib-0006){ref-type="ref"}, [7](#cas13130-bib-0007){ref-type="ref"}, [8](#cas13130-bib-0008){ref-type="ref"} and relevant pooling analyses[9](#cas13130-bib-0009){ref-type="ref"}, [10](#cas13130-bib-0010){ref-type="ref"}, [11](#cas13130-bib-0011){ref-type="ref"} have identified a number of susceptibility loci associated with ESCC risk in Chinese populations. However, these loci only explain a small fraction of the heritability of ESCC and the other genetic variants associated with ESCC risk need to be further explored. Of interest, the GWAS have shown that genetic variants located at chromosome 9p21.3, consisting of *MTAP*,*CDKN2A*,*CDKN2B*, and *CDKN2B‐AS1* genes, are related to multiple cancer risk, including glioma,[12](#cas13130-bib-0012){ref-type="ref"}, [13](#cas13130-bib-0013){ref-type="ref"}, [14](#cas13130-bib-0014){ref-type="ref"} melanoma,[15](#cas13130-bib-0015){ref-type="ref"}, [16](#cas13130-bib-0016){ref-type="ref"} basal cell carcinoma,[17](#cas13130-bib-0017){ref-type="ref"} nasopharyngeal carcinoma,[18](#cas13130-bib-0018){ref-type="ref"} breast cancer,[19](#cas13130-bib-0019){ref-type="ref"}, [20](#cas13130-bib-0020){ref-type="ref"} chronic lymphocytic leukemia,[21](#cas13130-bib-0021){ref-type="ref"} and childhood acute lymphoblastic leukemia.[22](#cas13130-bib-0022){ref-type="ref"} This evidence collectively suggests a pleiotropic effect of the 9p21.3 locus on cancer development.

Recently, Song *et al*.[23](#cas13130-bib-0023){ref-type="ref"} identified eight significantly mutated genes in ESCC, including *CDKN2A* located at the 9p21.3 region, by whole‐genome sequencing in 17 ESCC cases and whole‐exome sequencing in 71 ESCC cases. Subsequently, Gao *et al*.[24](#cas13130-bib-0024){ref-type="ref"} confirmed that genes involved in cell cycle and apoptosis regulation, including *CDKN2A*, were mutated in 99% of ESCC cases by sequencing on 113 tumor--normal pairs. These findings highlight the important role of genetic alterations at the 9p21.3 region in the development of ESCC and suggest that 9p21.3 may be a crucial genomic region for the regulation of ESCC development.

In the current study, we undertook a case--control study including 2139 ESCC cases and 2273 controls in a Chinese population, to investigate the role of genetic variants at 9p21.3 in ESCC susceptibility. We also evaluated the mRNA expression levels of *MTAP*,*CDKN2A*,*CDKN2B*, and *CDKN2B‐AS1* in paired ESCC tumor and adjacent normal tissues to further explore the genotype--phenotype correlation.

Materials and Methods {#cas13130-sec-0002}
=====================

Study subjects {#cas13130-sec-0003}
--------------

Esophageal squamous cell carcinoma cases were consecutively recruited from the Cancer Hospital of Jiangsu Province (Nanjing, China) and The Affiliated Huaian First People\'s Hospital of Nanjing Medical University (Huaian, China). All of the cases were histopathologically confirmed and the cases were excluded if they had a cancer history. A total of 2139 incident ESCC cases were included in this study. After being frequency‐matched to the cases on age (5‐year interval) and gender, 2273 controls were selected from cancer‐free participants in a community‐based screening program for non‐infectious diseases in Jiangsu province. All of the subjects were self‐reported ethnic Han Chinese. After signing informed consent, each subject was interviewed face‐to‐face with a standard questionnaire including information about demographic information and relevant risk factors, such as tobacco smoking and alcohol consumption. Each participant donated a \~5‐mL venous blood sample. The characteristics of cases and controls are shown in Table [S1](#cas13130-sup-0002){ref-type="supplementary-material"}. The cases had higher proportions of smokers and drinkers as compared with controls. This study was approved by the institutional review board of Nanjing Medical University (Nanjing, China).

Polymorphism selection strategy and genotyping assays {#cas13130-sec-0004}
-----------------------------------------------------

Genetic variants were selected mainly from the published GWAS that reported significant association between genetic variants located at chromosome 9p21.3 and the risk of various types of malignant tumor, including glioma (rs4977756; rs1412829),[12](#cas13130-bib-0012){ref-type="ref"}, [13](#cas13130-bib-0013){ref-type="ref"}, [14](#cas13130-bib-0014){ref-type="ref"} melanoma (rs7023329),[15](#cas13130-bib-0015){ref-type="ref"}, [16](#cas13130-bib-0016){ref-type="ref"} basal cell carcinoma (rs2151280),[17](#cas13130-bib-0017){ref-type="ref"} nasopharyngeal carcinoma (rs1412829),[18](#cas13130-bib-0018){ref-type="ref"} breast cancer (rs1011970),[19](#cas13130-bib-0019){ref-type="ref"}, [20](#cas13130-bib-0020){ref-type="ref"} chronic lymphocytic leukemia (rs1679013),[21](#cas13130-bib-0021){ref-type="ref"} and childhood acute lymphoblastic leukemia (rs3731217).[22](#cas13130-bib-0022){ref-type="ref"} In addition, a recent study explored the associations between common genetic variants in this region and multiple tumors, and confirmed that rs3731239 was significantly associated with ESCC in Chinese patients.[25](#cas13130-bib-0025){ref-type="ref"} We filtered the above reported variants according to the following items: (i) only one variant was selected as multiple one were in LD at *r* ^2^ \> 0.2 (1000 Genomes Project data of Chinese population, <http://browser.1000genomes.org/index.html>); (ii) those variants with a minor allele frequency \<5% in the Chinese population were excluded. Finally, we included rs7023329, rs3731217, rs3731239, rs1011970, and rs1679013 as tag SNPs to be genotyped in this study.

Genotyping was carried out using the TaqMan allelic discrimination assay on the ABI 7900 system (Applied Biosystems, Foster City, CA, USA). Two negative controls were included in each 384‐well plate for quality control. Detailed information regarding the primers and probes is shown in Table [S2](#cas13130-sup-0002){ref-type="supplementary-material"}. Technicians were blinded to the status of subjects (case or control) when carrying out the genotyping. The genotypes were called using the SDS 2.3 Allelic Discrimination Software (Applied Biosystems, Foster City, CA, USA).

RNA extraction, reverse transcription, and quantitative real‐time PCR assay {#cas13130-sec-0005}
---------------------------------------------------------------------------

Total RNA was extracted from ESCC tumor and adjacent normal tissues using TRIzol LS Reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer\'s protocol. The concentration of the RNA was measured by NanoDrop 2000 (Thermo Fisher Scientific, Waltham, MA, USA) and the absorbance values at 260 and 280 nm were acquired. All of the samples were of good quality, and 500 ng RNA was reverse transcribed to cDNA by using the PrimeScript RT Master Mix (TaKaRa, Kyoto, Japan) in accordance with the manufacturer\'s instructions. *MTAP*,*CDKN2A*, and *CDKN2B* mRNA expression levels were tested using the Hot Taq PCR Reaction Mix (BioSteed BioTechnologies, Nanjing, China), while quantitation of *CDKN2B‐AS1* transcripts was completed using SYBR Green labeling (TaKaRa, Kyoto, Japan) as implemented in the ABI 7900 real‐time PCR System (Applied Biosystems, Foster City, CA, USA). Experiments were carried out in duplicate in three independent assays. The results of mRNA expression were normalized using the threshold cycle of β*‐actin* (ACTB).

Statistical analysis {#cas13130-sec-0006}
--------------------

The chi‐square‐test was used to analyze distribution differences of the demographic characteristics, selected variables, and genotypes between cases and controls. The HWE was tested using a goodness‐of‐fit chi‐square‐test among the control subjects. Logistic regression analysis was used to test the association between SNPs and ESCC risk. The ORs and 95% CIs were calculated with adjustment for age, gender, smoking, and drinking status. The chi‐square‐based *Q*‐test was used to test the heterogeneity of effect sizes (ORs and 95% CIs) between subgroups.[26](#cas13130-bib-0026){ref-type="ref"} Linear regressing analysis was used to test the genotype--phenotype correlation. Paired two‐sample Student\'s *t*‐test was used to compare the *MTAP*,*CDKN2A*,*CDKN2B*, and *CDKN2B‐AS1* expression in paired tumor and non‐tumor tissues. All the statistical analyses were carried out using STATA version 12.0 software (STATA, College Station, TX, USA).

Results {#cas13130-sec-0007}
=======

Genotyping call rates were \>95% for all five SNPs and the observed genotype frequencies were all in agreement with HWE in the controls (Table [S3](#cas13130-sup-0002){ref-type="supplementary-material"}). The genotype distributions of the five SNPs between the cases and the controls are summarized in Table [1](#cas13130-tbl-0001){ref-type="table-wrap"}. In the additive model, the G allele of rs7023329 was significantly associated with a decreased risk of ESCC with a per‐allele OR of 0.84 (95% CI, 0.77--0.91; *P* = 2.95 × 10^−5^); in the codominant model, individuals carrying either AG or GG genotype showed a significantly reduced ESCC risk (OR = 0.68 and 0.72, respectively) compared with those with AA genotype. The C allele of rs1679013 was associated with an increased risk of ESCC with a per‐allele OR of 1.12 (95% CI, 1.01--1.24; *P* = 0.039) in the additive model, and in the codominant model, individuals carrying CC genotype showed an increased ESCC risk (OR = 1.44, 95% CI, 1.06--1.96; *P* = 0.020) compared with those with TT genotype. After conditioned on each other for these two SNPs, the association results for both variants changed little; rs1679013 and rs7023329 might be independent loci for ESCC susceptibility (Table [S4](#cas13130-sup-0002){ref-type="supplementary-material"}). Furthermore, subgroup analyses stratified by age, gender, and smoking and drinking status, were carried out for the association of two SNPs (rs7023329 and rs1679013) and ESCC risk. As shown in Table [2](#cas13130-tbl-0002){ref-type="table-wrap"}, there were no significant differences between subgroups (*P* \> 0.05 for heterogeneity tests) for associations of rs7023329 and rs1679013 with ESCC risk. However, no significant associations were observed for the other three SNPs with ESCC risk (additive *P* = 0.581, 0.909, and 0.183 for rs3731239, rs3731217, and rs1011970, respectively) (Table [1](#cas13130-tbl-0001){ref-type="table-wrap"}).

###### 

Summary of associations between genetic variants at 9p21.3 and esophageal squamous cell carcinoma risk in 2139 cases and 2273 controls in a Chinese population

  SNP         Cases, *n* (%)   Controls, *n* (%)   OR (95% CI)[a](#cas13130-note-0003){ref-type="fn"}   *P*‐value[a](#cas13130-note-0003){ref-type="fn"}
  ----------- ---------------- ------------------- ---------------------------------------------------- --------------------------------------------------
  rs7023329   *n* = 2121       *n* = 2239                                                               
  AA          706 (33.29)      576 (25.73)         1.00 (reference)                                     
  AG          950 (44.79)      1129 (50.42)        0.68 (0.59--0.79)                                    1.47 × 10^−7^
  GG          465 (21.92)      534 (23.85)         0.72 (0.61--0.85)                                    1.12 × 10^−4^
  G allele                                         0.84 (0.77--0.91)                                    2.95 × 10^−5^
  rs3731239   *n* = 2095       *n* = 2235                                                               
  TT          1572 (75.04)     1697 (75.93)        1.00 (reference)                                     
  TC          498 (23.77)      503 (22.51)         1.12 (0.97--1.29)                                    0.118
  CC          25 (1.19)        35 (1.75)           0.76 (0.45--1.18)                                    0.312
  C allele                                         0.96 (0.84--1.10)                                    0.581
  rs3731217   *n* = 2058       *n* = 2224                                                               
  TT          1325 (64.38)     1421 (63.89)        1.00 (reference)                                     
  TG          641 (31.15)      715 (32.15)         0.95 (0.83--1.08)                                    0.423
  GG          92 (4.47)        88 (3.96)           1.13 (0.83--1.53)                                    0.432
  G allele                                         0.99 (0.89--1.11)                                    0.909
  rs1011970   *n* = 2088       *n* = 2227                                                               
  GG          1745 (83.57)     1835 (82.40)        1.00 (reference)                                     
  GT          331 (15.85)      381 (17.11)         0.88 (0.75--1.03)                                    0.112
  TT          12 (0.57)        11 (0.49)           1.20 (0.52--2.75)                                    0.667
  T allele                                         0.90 (0.77--1.05)                                    0.183
  rs1679013   *n* = 2130       *n* = 2182                                                               
  TT          1247 (58.54)     1366 (62.60)        1.00 (reference)                                     
  TC          778 (36.53)      739 (33.87)         1.07 (0.94--1.21)                                    0.322
  CC          105 (4.93)       77 (3.53)           1.44 (1.06--1.96)                                    0.020
  C allele                                         1.12 (1.01--1.24)                                    0.039

Derived from logistic regression with an adjustment for age, sex, and smoking and drinking status. CI, confidence interval; OR, odds ratio.

John Wiley & Sons, Ltd

###### 

Stratified analyses of association between rs7023329 and rs1679013 and esophageal squamous cell carcinoma risk in 2139 cases and 2273 controls in a Chinese population

  Variables    rs7023329 (AA/AG/GG)   rs1679013 (TT/TC/CC)                                                                                                                           
  ------------ ---------------------- ---------------------- ------------------- --------------- ------------ -------------- ------------------- ------------------- --------------- -------
  Age, years                                                                                                                                                                         
  \<60         302/426/193            256/501/240            0.83 (0.73--0.94)   3.61 × 10^−3^   0.782        560/324/43     638/313/20          1.29 (1.09--1.52)   2.88 × 10^−3^   0.146
  ≥60          404/524/272            320/628/294            0.85 (0.76--0.95)   4.10 × 10^−3^   687/454/62   728/426/57     1.10 (0.96--1.26)   0.173                               
  Gender                                                                                                                                                                             
  Female       199/243/123            147/299/127            0.82 (0.70--0.97)   0.019           0.806        335/206/26     333/201/22          1.03 (0.84--1.26)   0.772           0.161
  Male         507/707/342            429/830/407            0.84 (0.76--0.93)   4.83 × 10^−4^   912/572/79   1,033/538/55   1.22 (1.08--1.38)   1.81 × 10^−3^                       
  Smoking                                                                                                                                                                            
  Never        325/440/211            283/560/262            0.83 (0.73--0.94)   2.28 × 10^−3^   0.892        581/353/43     666/373/39          1.09 (0.94--1.27)   0.248           0.232
  Ever         381/510/254            293/569/272            0.84 (0.75--0.95)   4.10 × 10^−3^   666/425/62   700/366/38     1.24 (1.07--1.44)   4.10 × 10^−3^                       
  Drinking                                                                                                                                                                           
  Never        366/497/237            372/706/356            0.82 (0.73--0.91)   3.85 × 10^−4^   0.590        644/413/46     873/478/52          1.12 (0.98--1.29)   0.112           0.431
  Ever         340/452/228            204/423/178            0.86 (0.75--0.98)   0.020           602/365/59   493/261/25     1.22 (1.04--1.44)   0.016                               

†Derived from additive model using logistic regression analyses with an adjustment for age, sex, smoking, and drinking status. ‡*P*‐values were from heterogeneity test based on chi‐square‐based *Q* test. CI, confidence interval; OR, odds ratio.

John Wiley & Sons, Ltd

Around the selected variants at 9p21.3 region, there are four important genes: *MTAP*,*CDKN2A*,*CDKN2B*, and *CDKN2B‐AS1* (Fig. [1](#cas13130-fig-0001){ref-type="fig"}). We next sought to determine whether rs7023329 and rs1679013 genotypes were associated with expression of these genes by quantitative RT‐PCR analysis of ESCC tumors and adjacent normal tissues (Figs [2](#cas13130-fig-0002){ref-type="fig"},[S1](#cas13130-sup-0001){ref-type="supplementary-material"}). We observed that the protective allele rs7023329‐G was related to a high expression of *MTAP* (*P* = 0.020), and the carriers of the risk allele rs1679013‐C had significantly lower expressions of *CDKN2B* than did non‐carriers (*P* = 0.035) among adjacent normal tissues (Fig. [2](#cas13130-fig-0002){ref-type="fig"}a,b). We found that *CDKN2B* was also significantly downregulated in ESCC tumor tissues compared with adjacent normal tissues (*P* = 3.50 × 10^−5^; Fig. [2](#cas13130-fig-0002){ref-type="fig"}c) while *CDKN2B‐AS1* was significantly upregulated (*P* = 3.34 × 10^−3^; Fig. [2](#cas13130-fig-0002){ref-type="fig"}d). These findings indicate that genetic variants at 9p21.3 may modulate the expression of *MTAP* and *CDKN2B* and contribute to ESCC susceptibility.

![Diagram showing the 9p21.3 locus containing the *MTAP*,*CDKN2A*,*CDKN2B*, and *CDKN2B‐AS1* genes and the five selected genetic variants. chr, chromosome; OR, odds ratio.](CAS-108-250-g001){#cas13130-fig-0001}

![Genotype‐phenotype correlation and differential expression analysis between esophageal squamous cell carcinoma (ESCC) tumor and adjacent normal tissues. (a, b) The relationship between genotype and expression for rs7023329 and *MTAP* (a), and rs1679013 and *CDKN2B* (b) in ESCC adjacent normal tissues. (c, d) Differential expressions of *CDKN2B* (c) and *CDKN2B‐AS1* (d) in paired ESCC tumor and adjacent normal tissues. ACTB, β‐actin.](CAS-108-250-g002){#cas13130-fig-0002}

Discussion {#cas13130-sec-0008}
==========

In this study, we investigated the associations of genetic variants at 9p21.3 with the risk of ESCC in a Chinese case--control study with 2139 cases and 2273 controls. We found that the G allele of rs7023329 was significantly associated with a reduced risk of ESCC, whereas the C allele of rs1679013 was associated with an increased risk of ESCC. Further genotype--phenotype analysis confirmed that the protective allele rs7023329‐G was related to a high expression of *MTAP*, which might increase the role of tumor suppressor MTAP. We also found that the carriers of the risk allele rs1679013‐C had lower expression of *CDKN2B* than did non‐carriers. *CDKN2B*, known as a tumor suppressor, was significantly downregulated in ESCC tumor tissues compared with adjacent normal tissues, which indicated that genetic variants at 9p21.3 may also be implicated with ESCC susceptibility. These findings may further improve our understanding of 9p21.3 locus in ESCC development.

The chromosome 9p21.3 region has been identified as a genetic susceptibility locus for a number of disease phenotypes, including heart disease, stroke, diabetes, and especially cancers.[27](#cas13130-bib-0027){ref-type="ref"}, [28](#cas13130-bib-0028){ref-type="ref"}, [29](#cas13130-bib-0029){ref-type="ref"} Recently, several GWAS have confirmed that variants in this region are related to multiple cancer risks, including glioma,[12](#cas13130-bib-0012){ref-type="ref"}, [13](#cas13130-bib-0013){ref-type="ref"}, [14](#cas13130-bib-0014){ref-type="ref"} melanoma,[15](#cas13130-bib-0015){ref-type="ref"}, [16](#cas13130-bib-0016){ref-type="ref"} basal cell carcinoma,[17](#cas13130-bib-0017){ref-type="ref"} nasopharyngeal carcinoma,[18](#cas13130-bib-0018){ref-type="ref"} breast cancer,[19](#cas13130-bib-0019){ref-type="ref"}, [20](#cas13130-bib-0020){ref-type="ref"} chronic lymphocytic leukemia,[21](#cas13130-bib-0021){ref-type="ref"} and childhood acute lymphoblastic leukemia.[22](#cas13130-bib-0022){ref-type="ref"} These associations suggest that multiple functional genetic variants may exist in this region and the genetic variants at 9p21.3 may also be pleiotropic.

Two studies have reported that genetic variants in 9p21.3 (including rs3731239, rs1063192, rs2157719, rs615552, rs573687, rs4977756, and rs564398) were associated with ESCC in a Chinese population.[25](#cas13130-bib-0025){ref-type="ref"}, [29](#cas13130-bib-0029){ref-type="ref"} These variants mainly represent three independent signals according to the LD pattern in the 1000 Genomes Project data of Chinese population: signal 1, rs1063192 and rs4977756 (*r* ^2^ = 0.91); signal 2, rs2157719, rs615552, rs573687, and rs564398 (*r* ^2^ = 1.00); and signal 3, rs3731239. However, our findings with a larger sample size did not find a significant association between rs3731239 (signal 3) and ESCC risk. Instead, we found that rs7023329 and rs1679013 were independently associated with ESCC risk. These two variants were also not in LD with previous reported variants (*r* ^2^ \< 0.1). However, large well‐designed studies are warranted to further confirm our findings.

Recent studies showed that the 9p21.3 region was enriched in regulatory sequences such as enhancers that regulate the expression of genes in this region and downstream, thereby establishing a functional link between 9p21 genetic variation and immune signaling pathways.[30](#cas13130-bib-0030){ref-type="ref"} Our results confirmed that the carriers of the protective allele rs7023329‐G had significantly higher expressions of *MTAP* than did non‐carriers among adjacent normal tissues. It has been reported that loss of *MTAP* expression can exert a tumor‐promoting effect in multiple cancers and *MTAP* may function as a tumor suppressor gene.[31](#cas13130-bib-0031){ref-type="ref"}, [32](#cas13130-bib-0032){ref-type="ref"}, [33](#cas13130-bib-0033){ref-type="ref"} Therefore, the rs7023329‐G allele was related to high expression of *MTAP*, which might increase the role of tumor suppressor MTAP and ultimately result in a reduced ESCC risk. Moreover, the ESCC‐risk allele rs1679013‐C was associated with reduced *CDKN2B* expression in our study. Analysis of the Encyclopedia of DNA Elements data, as implemented in the online tool HaploReg (<http://broadinstitute.org/mammals/haploreg/haploreg.php>), indicated that rs1679013 was located in a transcription regulatory region and may influence the chromatin structure and histone modifications by altering the transcription factor binding sites of *OTX2*, which may serve as a regulatory variant in the expression of *CDKN2B*, suggesting that modulation of *CDKN2B* expression may mediate ESCC susceptibility. *CDKN2B* encodes the p15^INK4B^ protein, which was subject to frequent inactivation in human primary ESCC.[34](#cas13130-bib-0034){ref-type="ref"} Moreover, *CDKN2B* has previously been linked to cellular senescence and shown to act as a tumor suppressor protein.[35](#cas13130-bib-0035){ref-type="ref"}, [36](#cas13130-bib-0036){ref-type="ref"} Our data showed that *CDKN2B* was significantly downregulated in ESCC tumor tissues compared with adjacent normal tissues, suggesting that *CDKN2B* underexpression may also mediate susceptibility to ESCC in Chinese patients. These data suggest that genetic variants in the *MTAP/CDKN2A/2B/2B‐AS1* cluster may modulate ESCC susceptibility through regulating expression levels of genes in the cluster. Although we evaluated the possible mechanism by genotype--phenotype analysis and bioinformatics annotations, it is not enough to illustrate the exact biological function between these variants and ESCC. Further functional evaluations are warranted to further clarify these findings.

In summary, in a relatively large case--control study in a Chinese population, we found two independent variants in 9p21.3 (rs7023329 and rs1679013) associated with ESCC risk and provided additional evidence for the role of 9p21.3 locus in ESCC development. Further work is needed to validate our findings in diverse ethnic populations and to clarify the functional variants at 9p21.3 contributing to the development of ESCC.
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**Fig. S1.** Genotype--phenotype correlation and differential expression analysis between esophageal squamous cell carcinoma tumor and adjacent normal tissues.
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**Table S1.** Comparison of characteristics between esophageal squamous cell carcinoma cases and controls.
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